NBIX
NASDAQStockNeurocrine Biosciences, Inc.
$128.03-1.51 (-1.17%)
52-Week Range
$87.54
$155.63
Key Stats
Market Cap
12.8B
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.36
Volume
457.7K
Avg Volume
1.0M
Performance
1M
-7.03%
3M
-17.06%
6M
-9.01%
YTD
-9.12%
1Y
+17.24%
3Y
+33.83%
5Y
+31.64%
Price Chart
ETF Exposure
NBIX is held by 216 ETFs
| ETF | Fund Name | Weight |
|---|---|---|
| PSIL | AdvisorShares Psychedelics ETF | 5.58% |
| MNTL | Tema Neuroscience And Mental Health ETF | 4.89% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.42% |
| IBRN | iShares Neuroscience and Healthcare ETF | 3.36% |
| PBE | Invesco Biotechnology & Genome ETF | 2.84% |
| FTGS | First Trust Growth Strength ETF | 2.00% |
| FGSI | FT Vest Growth Strength & Target Income ETF | 1.99% |
| DEF | Invesco Defensive Equity ETF | 1.85% |
| POWA | Invesco Bloomberg Pricing Power ETF | 1.85% |
| INVN | Alger Russell Innovation ETF | 1.77% |
| BBH | VanEck Biotech ETF | 1.75% |
| BUL | Pacer US Cash Cows Growth ETF | 1.66% |
| HELX | Franklin Genomic Advancements ETF | 1.61% |
| HEAL.L | iShares Healthcare Innovation UCITS ETF | 1.52% |
| HAPY | Harbor Human Capital Factor Unconstrained ETF (HAPY) | 1.48% |
| ROCI | ROC ETF | 1.38% |
| ILDR | First Trust Innovation Leaders ETF | 1.33% |
| BBP | Virtus Biotech ETF | 1.30% |
| FXH | First Trust Health Care AlphaDEX Fund | 1.26% |
| RFG | Invesco S&P MidCap 400 Pure Growth ETF | 1.11% |
| IBB | iShares Biotechnology ETF | 1.10% |
| FSGS | First Trust SMID Growth Strength ETF | 1.03% |
| XBI | State Street SPDR S&P Biotech ETF | 1.02% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.98% |
| AGRW | Allspring LT Large Growth ETF | 0.97% |
| AGNG | Global X - Aging Population ETF | 0.84% |
| LNGR | Global X Aging Population ETF | 0.84% |
| IVOG | Vanguard S&P Mid-Cap 400 Growth ETF | 0.79% |
| IJK | iShares S&P Mid-Cap 400 Growth ETF | 0.75% |
| MDYG | State Street SPDR S&P 400 Mid Cap Growth ETF | 0.74% |
| BIB | ProShares - Ultra Nasdaq Biotechnology | 0.67% |
| QQQJ | Invesco NASDAQ Next Gen 100 ETF | 0.66% |
| MRND | IQ U.S. Mid Cap R&D Leaders ETF | 0.65% |
| DSTL | Distillate U.S. Fundamental Stability & Value ETF | 0.61% |
| MIDE | Xtrackers S&P MidCap 400 Scored & Screened ETF | 0.61% |
| FLQM | Franklin U.S. Mid Cap Multifactor Index ETF | 0.60% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 0.59% |
| QQJG | Invesco ESG NASDAQ Next Gen 100 ETF | 0.59% |
| JDOC | JPMorgan Healthcare Leaders ETF | 0.56% |
| FNY | First Trust Mid Cap Growth AlphaDEX Fund | 0.53% |
| ISCG | iShares Morningstar Small-Cap Growth ETF | 0.46% |
| JKK | iShares Morningstar Small-Cap Growth ETF | 0.46% |
| QLV | FlexShares US Quality Low Volatility Index Fund | 0.45% |
| XJH | iShares ESG Select Screened S&P Mid-Cap ETF | 0.45% |
| SMOX | Horizon Small/Mid Cap Core Equity ETF | 0.44% |
| SDG | iShares MSCI Global Sustainable Development Goals ETF | 0.43% |
| QVMM | Invesco S&P MidCap 400 QVM Multi-factor ETF | 0.43% |
| VBK | Vanguard Small-Cap Growth ETF | 0.42% |
| IVOO | Vanguard S&P Mid-Cap 400 ETF | 0.40% |
| SPMD | State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.39% |
Page 1 of 5Next
About NBIX ETF Exposure
Neurocrine Biosciences, Inc. (NBIX) is held by 216 exchange-traded funds, making it one of the stocks with significant ETF exposure. With a market capitalization of 12.8B, NBIX is a widely held institutional stock. The stock currently trades at $128.03. Investors can gain exposure to NBIX through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold NBIX, sorted by portfolio weight.